Bone densitometry firm CompuMed announced last week that it has successfully acquired images using both dual-energy x-ray absorptiometry and amorphous silicon x-ray detectors. The Manhattan Beach, CA, firm believes that being able to acquire such images
Bone densitometry firm CompuMed announced last week that it has successfully acquired images using both dual-energy x-ray absorptiometry and amorphous silicon x-ray detectors. The Manhattan Beach, CA, firm believes that being able to acquire such images will help the company in its development of Digital OsteoView 2000, a device designed to detect both osteoporosis and arthritis.
CompuMed scientists working with researchers at the University of Massachusetts used amorphous silicon flat-panel detectors licensed from Varian Associates, with whom CompuMed has an OEM agreement (SCAN 1/8/97). CompuMed plans to file for 510(k) clearance for Digital OsteoView 2000 later this year.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.